BRITANNIA LIFE SCIENCES - Asset Resilience Ratio
BRITANNIA LIFE SCIENCES (L020) has an Asset Resilience Ratio of 63.76% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BRITANNIA LIFE SCIENCES (L020) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how BRITANNIA LIFE SCIENCES's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see BRITANNIA LIFE SCIENCES asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down BRITANNIA LIFE SCIENCES's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of BRITANNIA LIFE SCIENCES to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €14.07 Million | 63.76% |
| Total Liquid Assets | €14.07 Million | 63.76% |
Asset Resilience Insights
- Very High Liquidity: BRITANNIA LIFE SCIENCES maintains exceptional liquid asset reserves at 63.76% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BRITANNIA LIFE SCIENCES Industry Peers by Asset Resilience Ratio
Compare BRITANNIA LIFE SCIENCES's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for BRITANNIA LIFE SCIENCES (None–None)
The table below shows the annual Asset Resilience Ratio data for BRITANNIA LIFE SCIENCES.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About BRITANNIA LIFE SCIENCES
Britannia Life Sciences Inc. engages in the product testing, safety assessment, and manufacturing services in the United Kingdom and internationally. It serves cosmetics, consumer packaged and household goods, and nutraceutical industries. The company is headquartered in Toronto, Canada.